Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (74)
  2. Journal Article (20)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (1)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (108)
  2. Hematologic Malignancies, Division of (108)
  3. Center for Hematologic Malignancies (68)
  4. Lymphoma (58)
  5. Survivorship Research (45)
  6. Sloan Kettering Institute Postdocs (42)

More Groups

People
  1. Andrew Zelenetz (50)
  2. Gilles Salles (48)
  3. Anita Kumar (46)
  4. Maria Palomba (45)
  5. Ariela Noy (43)
  6. Alison Moskowitz (40)

More People

Years
  1. 2025 (5)
  2. 2024 (17)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (5)
  6. American Journal of Hematology (4)

More Publications

Publishers
  1. American Society of Hematology (50)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (7)
  5. Ferrata Storti Foundation (4)
  6. John Wiley & Sons (4)

More Publishers

Results (108)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Epcoritamab + R (2) regimen and responses in high-risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Merryman, R.; Belada, D.; Sureda, A.; Leppä, S.; Vermaat, J. S. P.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
    Meeting Abstract

    Falchi, L.; Clausen, M.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Sarkar, R.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Lee, J.; Salles, G.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • High complete metabolic response rates with epcoritamab + R‐CHOP in previously untreated (1L) high‐risk DLBCL, including double‐hit/triple‐hit: EPCORE NHL‐2 update
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL): Extended follow‐up and landmark analyses from a pivotal phase II study
    Meeting Abstract

    Dickinson, M.; Carlo‐Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez‐Lopez, J.; Bartlett, N.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high‐risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Belada, D.; Falchi, L.; Leppä, S.; Vermaat, J. S.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; Nijland, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Small volume biopsy diagnostic yield at initial diagnosis versus recurrence/transformation of follicular lymphoma: A retrospective Cyto-Heme Interinstitutional Collaborative study
    Journal Article

    Fitzpatrick, M. J.; Sundaram, V.; Ly, A.; Abramson, J. S.; Balassanian, R.; Cheung, M. C.; Cook, S. L.; Falchi, L.; Frank, A. K.; Gupta, S.; more...
    Cancer Cytopathology (2023)

    Fulltext@MSK | Save